Heart valve disease in children and young adults is a categorically different clinical problem from the same diagnosis in a 70-year-old. The treatment decisions carry consequences that extend across decades of active life, not years. A mechanical valve implanted in a child will need anticoagulation for life and will likely require reoperation as the child grows. A tissue valve will degenerate faster in a younger, physiologically more demanding heart. A repair, if achievable, avoids both problems but demands surgical skill and institutional experience that is not universally available. The Ross procedure, which replaces the diseased aortic valve with the patient's own pulmonary valve, provides a living autograft that can grow with the child, does not require anticoagulation, and in expert hands delivers survival equivalent to the age-matched general population.
For parents and young adults navigating heart valve disease, understanding what the treatment options are, how age changes the decision-making, and how India's leading paediatric and adult congenital heart centres provide this level of care is the essential starting point.
Why Age Changes Everything in Heart Valve Disease Treatment
Heart valve disease in a child or young adult cannot be treated using the same decision framework applied to older adults. Three age-specific factors define the difference.
Growth
A child's heart grows as the child does. An implanted prosthetic valve does not. A valve sized for a child of seven will be undersized for that child at fourteen, producing progressive obstruction and requiring reoperation. This growth imperative drives most of the technical creativity in paediatric valve surgery and makes repair strongly preferred over replacement whenever anatomically possible.
Long Life Expectancy and Activity Level
A young adult with a mechanical valve faces 40 to 60 years of anticoagulation, with its attendant risks of bleeding and thromboembolism across decades. A tissue valve in a young patient degenerates faster than in older patients because the metabolic and haemodynamic demands of a younger, more active physiology accelerate structural valve deterioration. The ideal treatment for a young patient is one that does not require lifelong anticoagulation and does not degenerate within the patient's expected lifetime.
Congenital Versus Acquired Aetiology
Children most commonly develop heart valve disease from congenital anatomical abnormalities: bicuspid aortic valve, pulmonary valve stenosis, mitral valve prolapse, or complex congenital heart disease involving multiple valves. Young adults additionally develop rheumatic heart disease, the most common cause of valve disease in developing countries, from rheumatic fever following Group A streptococcal infection. The aetiology influences which valve is affected, the anatomy the surgeon encounters, and the technical approach required.
The Treatment Options for Heart Valve Disease in Children and Young Adults
Balloon Valvuloplasty: The Catheter-Based First Step
For pulmonary valve stenosis and selected cases of aortic valve stenosis, balloon valvuloplasty is the preferred initial treatment. A catheter is passed through the femoral vein or artery, navigated to the valve, and a balloon inflated across the stenotic valve to separate fused leaflets and improve opening. It is performed without open-heart surgery or general anaesthesia in most cases, and produces immediate haemodynamic improvement in suitable candidates.
Balloon valvuloplasty for pulmonary stenosis produces excellent long-term results with low reintervention rates and is considered the definitive treatment for this indication. For aortic stenosis, it is a temporising measure in most cases, bridging the patient to a more definitive surgical intervention when anatomy is appropriate.
Surgical Valve Repair
Valve repair preserves the native valve leaflets and subvalvar apparatus, avoiding the need for a prosthetic device entirely. It is strongly preferred over replacement whenever technically achievable because it avoids the specific risks of prosthetic valves and, for the mitral valve, preserves left ventricular function better than replacement.
For mitral valve disease, surgical repair techniques include leaflet resection, chordal shortening or replacement with artificial chords, annuloplasty ring implantation, and commissurotomy for rheumatic mitral stenosis. A 2025 meta-analysis confirming satisfactory outcomes with aortic valve repair and demonstrating that reintervention can often be postponed for several years supports the role of repair as a bridge to more definitive surgery in carefully selected paediatric patients.
For aortic valve disease in young adults, repair techniques including leaflet extension with pericardium, raphe resection in bicuspid valves, and commissurotomy for calcific disease are used by surgeons with high-volume aortic valve repair experience.
The Ross Procedure: The Most Important Option for Young Patients
The Ross procedure is the most clinically significant surgical option for aortic valve disease in children and young adults, and understanding it is central to understanding what is the treatment for heart valve disease in this age group.
The procedure replaces the diseased aortic valve with the patient's own pulmonary valve (a pulmonary autograft). The pulmonary valve, which operates at lower pressure than the aortic valve in the right heart, adapts progressively to the higher-pressure aortic environment after transplantation. A donor homograft (cryopreserved human cadaveric valve) or a tissue bioprosthesis is then implanted in the pulmonary position to restore right ventricular outflow.
Key advantages of the Ross procedure for children and young adults:
- The autograft is a living valve with growth potential, which is critical in children whose hearts will increase in size
- No anticoagulation is required after surgery, eliminating lifelong warfarin
- Haemodynamic performance mirrors that of a normal native aortic valve, even during strenuous physical activity
- The Ross procedure provides survival equivalent to that of the age and gender-matched general population, unlike prosthetic or homograft replacement which carries a lifetime survival disadvantage
- In isolated cases without annulus enlargement, operative mortality is 0.4 percent based on the 2025 European Congenital Heart Surgeons Association database analysis of 2,129 patients
The 2025 ECSA database analysis covering a decade of aortic valve surgery in adolescents and young adults confirmed an increase in the use of the Ross procedure over time, reflecting the growing recognition of its superiority for this age group. The overall operative mortality was 1.5 percent across all approaches, with the Ross procedure in isolated cases achieving 0.4 percent.
The principal limitation of the Ross procedure is its technical complexity, which demands a surgeon with specific experience and an institutional programme built around its safe execution. Not every cardiac surgery centre offering valve replacement also offers the Ross procedure, and this distinction matters significantly for young patients.
Mechanical Valve Replacement
A mechanical valve is the most durable prosthetic option, designed to last for decades without structural deterioration. The key limitation in young patients is the requirement for lifelong anticoagulation with warfarin, with its attendant risks of haemorrhage and thromboembolism over 40 to 60 years. Female patients of reproductive age face the additional complexity of managing anticoagulation through pregnancy, where both warfarin and the alternatives carry specific risks for the developing foetus.
For children, the growth problem is decisive: a mechanical valve implanted in a small child will require reoperation as the annulus outgrows the prosthesis, making it a temporising option in the youngest patients rather than a definitive solution.
Tissue Valve Replacement
Tissue valves (bioprosthetic valves made from bovine or porcine pericardium) avoid the anticoagulation requirement of mechanical valves but degenerate faster in young patients. Structural valve deterioration leading to reoperation within 10 to 15 years is significantly more common in patients under 40 than in older recipients, making tissue valves a less favourable primary choice for children and young adults unless other factors make mechanical or autograft options less suitable.
Homografts (cryopreserved human cadaveric valves) avoid anticoagulation and have better haemodynamic profiles than bioprosthetics, but degenerate over time and require reoperation, typically within 10 to 20 years in younger patients.
Transcatheter Valve Intervention
Transcatheter aortic valve implantation (TAVI) and transcatheter pulmonary valve implantation have been primarily developed and validated in older adult populations. In children and young adults, transcatheter pulmonary valve implantation (e.g., Melody valve) is increasingly used for pulmonary valve replacement in patients with prior right ventricular outflow tract reconstruction, avoiding repeat open-heart surgery. Transcatheter options for aortic valve disease in young patients remain under investigation and are not yet standard practice for this age group.
Heart Valve Disease in Children and Young Adults: India's Clinical Capability
India has one of the highest burdens of rheumatic heart disease in the world, which has driven the development of surgical and catheter-based valve expertise at leading cardiac centres that is directly relevant to young patients from South Asia, East Africa, and the Middle East.
Where India's Valve Expertise Is Concentrated
India's leading paediatric and congenital heart disease programmes are based in centres including:
-
Aster Medcity Kochi: JCI and NABH-accredited, with a dedicated paediatric cardiac surgery programme. Dr. Edwin Francis leads paediatric cardiac surgery with specific expertise in congenital heart disease including valve surgery. For context on Aster Medcity's paediatric cardiac programme, read: https://karetrip.com/blogs/pediatric-heart-surgery-in-india-a-complete-guide
-
Apollo Hospitals Chennai, Delhi, and Hyderabad: High-volume congenital and adult valve surgery programmes with Ross procedure capability at select units
-
Narayana Health (NH) Bangalore and Kolkata: Among India's highest-volume paediatric cardiac surgery centres globally, with one of the largest rheumatic valve disease programmes in the world
-
AIIMS Delhi and SCTIMST Thiruvananthapuram: Academic centres with the most comprehensive congenital heart disease programmes in India's public sector
Cost of Heart Valve Treatment in India for International Patients
| Procedure | India cost | USA / UK equivalent |
|---|---|---|
| Balloon pulmonary valvuloplasty | Rs. 80,000 to Rs. 1,50,000 (USD 960 to USD 1,800) | USD 10,000 to USD 25,000 |
| Surgical valve repair (mitral or aortic) | Rs. 2,50,000 to Rs. 5,00,000 (USD 3,000 to USD 6,000) | USD 40,000 to USD 80,000 |
| Ross procedure | Rs. 4,00,000 to Rs. 8,00,000 (USD 4,800 to USD 9,600) | USD 60,000 to USD 150,000 |
| Mechanical valve replacement | Rs. 2,00,000 to Rs. 4,50,000 (USD 2,400 to USD 5,400) | USD 30,000 to USD 70,000 |
| Transcatheter pulmonary valve (Melody) | Rs. 5,00,000 to Rs. 8,00,000 (USD 6,000 to USD 9,600) | USD 50,000 to USD 120,000 |
All represent savings of 60 to 85 per cent versus the USA or UK.
How Karetrip Connects International Patients to Paediatric and Young Adult Valve Surgery in India
Heart valve surgery in children and young adults requires a surgeon and centre with specific experience in the age-specific approaches — particularly valve repair and the Ross procedure — that produce the best long-term outcomes for this population. Karetrip reviews each patient's echocardiography reports, catheterisation data where available, and prior surgical history before recommending a centre, confirming that the proposed surgical team has the specific expertise and case volume in the procedure required.
From pre-travel imaging review and medical visa coordination, through accommodation near the treating hospital and discharge documentation for continued cardiological follow-up at home, Karetrip manages the complete international patient journey for heart valve disease treatment in India.
Chat with our Medical care assistant, RUA, for quick guidance and support and take the first step toward expert heart valve assessment and surgery for your child or young adult family member in India.